Tyrosine-protein kinase receptor TIE-2 (component of Angiopoietin–Tie-2 signaling pathway) (TIE2 or TEK (gene name))

The Angiopoietin–Tie-2 signaling pathway is a vascular-specific receptor tyrosine kinase system essential for blood and lymphatic vascular homeostasis and endothelial stability.[1][2][3] TIE2 is the central transmembrane receptor in this pathway, functioning as a molecular rheostat for vascular quiescence when activated by its ligands, particularly Angiopoietin-1, which directly binds to TIE2 and triggers phosphorylation and downstream PI3-kinase/AKT and ERK signaling.[1][3] Activation of TIE2 maintains stable endothelial junctions, prevents vascular leakage, reduces inflammation, and suppresses inappropriate coagulation—effects critical for maintaining microvascular health during homeostasis.[3] However, in disease states including sepsis, acute respiratory distress syndrome, acute kidney injury, and cancer, disruption of TIE2 signaling through elevated Angiopoietin-2 (a context-dependent antagonist) or overexpression of the negative regulator VE-PTP leads to vascular destabilization, increased permeability, inflammation, and pathological outcomes.[1][3][4] Therapeutically, this pathway is being targeted through recombinant Angiopoietin-1 delivery, Angiopoietin-2 neutralizing antibodies, and VE-PTP inhibitors to restore vascular stability and reduce organ dysfunction in critical illness and cancer.[2][3] Multiple "shovel-ready" therapeutic approaches are in clinical or late preclinical development, positioning TIE2 as a promising therapeutic target for conditions characterized by vascular dysfunction.

Other names

Tyrosine-protein kinase receptor TIE-2TEK (gene symbol)Tie2CD202bEndothelial cell-specific receptor tyrosine kinaseAngiopoietin receptorAngiopoietin-1 receptor (primary ligand)

Angiopoietin-1 agonism: Activates TIE2 through direct binding, inducing phosphorylation and clustering of TIE2 monomers into efficient signaling units, activating downstream PI3-kinase/AKT and ERK pathways[1][3] Angiopoietin-2 context-dependent modulation: Acts as a competitive antagonist in blood endothelium (in presence of VE-PTP) but functions as an agonist in lymphatic endothelium (where VE-PTP is absent)[2][4] VE-PTP inhibition: Prevents dephosphorylation of TIE2, maintaining its activated state and allowing TIE2 activation even by the weak agonist Angiopoietin-2, converting it to function like the strong agonist Angiopoietin-1[2] Vascular stabilization: Tie2 activation promotes endothelial barrier function, reduces vascular permeability, and stabilizes vessel junctions through Rap1-mediated regulation of Rac1 and cortical actin cytoskeleton stabilization[5] Anti-inflammatory effects: Tie2 signaling prevents excessive fibrin accumulation, inhibits tissue factor exposure, and reduces inflammatory mediator responsiveness[3]